Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.63 |
| ▸ | MMP2 | P08253 | 3/20 | 0.58 |
| ▸ | MMP8 | P22894 | 2/20 | 0.58 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 4/20 | 0.57 |
| ▸ | ECE1 | P42892 | 5/20 | 0.57 |
| ▸ | IL1RN | P18510 | 6/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720482 | 0.97 | ERAP2 (0.64) | ERAP2MMP2MMP8MMP1MMP9 | |
| SCHEMBL31720547 | 0.94 | ERAP2 (0.66) | ERAP2MMP2MMP8MMP1MMP9 | |
| SCHEMBL31720495 | 0.94 | ERAP2 (0.63) | ERAP2GHSRECE1IL1RNERAP1 | |
| SCHEMBL30788023 | 0.93 | ERAP2 (0.63) | ERAP2MMP2MMP8MMP1MMP9 | |
| SCHEMBL31232500 | 0.93 | ERAP2 (0.63) | ERAP2GHSRECE1IL1RNERAP1 | |
| SCHEMBL30465909 | 0.93 | ERAP2 (0.70) | ERAP2MMP2MMP8MMP1MMP9 | |
| SCHEMBL29505127 | 0.92 | GHSR (0.62) | ERAP2GHSRIL1RNERAP1 | |
| SCHEMBL30518838 | 0.91 | ERAP2 (0.61) | ERAP2GHSRIL1RNERAP1EDNRA | |
| SCHEMBL29691762 | 0.91 | ERAP2 (0.70) | ERAP2MMP2MMP8MMP1MMP9 | |
| SCHEMBL30507632 | 0.91 | GHSR (0.63) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | ERAP2 257/4885MMP2 284/4885MMP8 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.